Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.57M$7.57Mderivedno prior Q4 2023 on file Net Income-$206.48M-$206.48MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$284,965,000N/M Operating Cash Flowderived-$172,565,000N/M Free Cash Flowderived-$173,376,000N/M Margins · derivedOperating margin-3764.4%
Net margin-2727.5%
ended Mar 31, 2025 · filed May 29, 2025 · 59 d after period end